Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); New Treatments in Prostate Cancer Could Leave Provenge Behind
Tweet Send to a Friend
Wedbush reiterates an 'Underperform' on Dendreon (NASDAQ: DNDN) price target of $4.00 (from $5.00).
Analyst, David M. Nierengarten, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, David M. Nierengarten, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
